Page 29 - GTM-4-3

Global Translational Medicine Anti-inflammatory therapy in CVD

34. Lelios I, Cansever D, Utz SG, Mildenberger W, Stifter SA, spesolimab for generalized pustular psoriasis. N Engl J Med.
Greter M. Emerging roles of IL-34 in health and disease. 2021;385(26):2431-2440.
J Exp Med. 2020;217(11):e20190290.
doi: 10.1056/NEJMoa2111563
doi: 10.1084/jem.20190290
41. Kelsen SG, Agache IO, Soong W, et al. Astegolimab
35. Yuan ZC, Xu WD, Liu XY, Liu XY, Huang AF, Su LC. Biology
of IL-36 signaling and its role in systemic inflammatory (anti-ST2) efficacy and safety in adults with severe asthma:
diseases. Front Immunol. 2019;10:2532. A randomized clinical trial. J Allergy Clin Immunol.
2021;148(3):790-798.
doi: 10.3389/fimmu.2019.02532
doi: 10.1016/j.jaci.2021.03.044
36. Broch K, Anstensrud AK, Woxholt S, et al. Randomized
trial of interleukin-6 receptor inhibition in patients with 42. Dou M, Chen Y, Hu J, Ma D, Xing Y. Recent advancements
acute ST-segment elevation myocardial infarction. J Am Coll in CD47 signal transduction pathways involved in vascular
Cardiol. 2021;77(15):1845-1855. diseases. Biomed Res Int. 2020;2020:4749135.
doi: 10.1016/j.jacc.2021.02.049
doi: 10.1155/2020/4749135
37. Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in
plaque psoriasis--results of two phase 3 trials. N Engl J Med. 43. Yarmohammadi F, Karimi G. The role of SGK1 in
2014;371(4):326-338. cardiovascular disease: Molecular mechanisms and clinical
implications. Pharmacol Res. 2024;208:107369.
doi: 10.1056/NEJMoa1314258
doi: 10.1016/j.phrs.2023.107369
38. Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety
of ustekinumab, a human interleukin-12/23 monoclonal 44. Escopy S, Chaikof EL. Targeting the P-selectin/PSGL-1
antibody, in patients with psoriasis: 76-week results from pathway: Discovery of disease-modifying therapeutics for
a randomised, double-blind, placebo-controlled trial disorders of thromboinflammation. Vessels Thromb Hemost.
(PHOENIX 1). Lancet. 2008;371(9625):1665-1674.
2024;1(3):100015.
doi: 10.1016/S0140-6736(08)60725-4
doi: 10.1016/j.bvth.2024.100015
39. Gordon KB, Foley P, Krueger JG, et al. Bimekizumab
efficacy and safety in moderate to severe plaque psoriasis 45. Di Candia AM, Avila DX, Moreira GR, Villacorta H,
(BE READY): A multicentre, double-blind, placebo- Maisel AS. Growth differentiation factor-15, a novel
controlled, randomised withdrawal phase 3 trial. Lancet. systemic biomarker of oxidative stress, inflammation, and
2021;397(10275):475-486. cellular aging: Potential role in cardiovascular diseases. Am
doi: 10.1016/S0140-6736(21)00126-4 Heart J Plus. 2021;9:100046.
40. Bachelez H, Choon SE, Marrakchi S, et al. Trial of doi: 10.1016/j.ahjo.2021.100046

Volume 4 Issue 3 (2025) 21 doi: 10.36922/GTM025100024